ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Up 47.6% in November

ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 283,200 shares, an increase of 47.6% from the October 31st total of 191,900 shares. Based on an average daily volume of 122,700 shares, the days-to-cover ratio is presently 2.3 days. Approximately 0.5% of the company's shares are sold short.

ABIVAX Société Anonyme Stock Down 0.4 %

ABIVAX Société Anonyme stock traded down $0.03 during mid-day trading on Friday, hitting $8.53. 56,118 shares of the stock were exchanged, compared to its average volume of 93,885. ABIVAX Société Anonyme has a 12 month low of $8.23 and a 12 month high of $17.02. The firm's fifty day simple moving average is $10.05 and its two-hundred day simple moving average is $11.77.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of ABVX. BNP Paribas Financial Markets increased its stake in ABIVAX Société Anonyme by 82.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company's stock valued at $150,000 after purchasing an additional 5,900 shares in the last quarter. Kennedy Capital Management LLC increased its stake in ABIVAX Société Anonyme by 35.3% during the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company's stock valued at $1,718,000 after purchasing an additional 31,331 shares in the last quarter. Walleye Capital LLC increased its stake in ABIVAX Société Anonyme by 45.8% during the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company's stock valued at $2,965,000 after purchasing an additional 80,807 shares in the last quarter. abrdn plc increased its stake in ABIVAX Société Anonyme by 167.7% during the 3rd quarter. abrdn plc now owns 316,431 shares of the company's stock valued at $3,645,000 after purchasing an additional 198,225 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its stake in ABIVAX Société Anonyme by 28.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company's stock valued at $6,254,000 after purchasing an additional 119,300 shares in the last quarter. Institutional investors and hedge funds own 47.91% of the company's stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.